Trial Profile
Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2011
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2011 New trial record